Commercializing Biomarkers of Disease-Modification for Decision Making in Drug Development, Diagnosis and Therapeutic Monitoring
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130205:nBw056190a David Fineman, CEO, will present KineMed's revolutionary biomarker platform, which enables better healthcare management in the era of personalized medicine, at BIO CEO & Investor 2013 EMERYVILLE, Calif.--(Business Wire)-- KineMed, Inc. (www.kinemed.com) announced today that David Fineman, President and CEO of KineMed, Inc. will present at the 15th Annual BIO CEO & Investor Conference taking place February 11th - 12th, 2013 at the Waldorf Astoria, New York. Mr. Fineman will present on February 11th at 1:30 p.m. EST in the Park South room. Mr. Fineman`s presentation, entitled "Functionally Interpretable Biomarkers For The Next Generation Of Disease Management" will highlight opportunities in the multi-billion dollar commercial landscape created across the healthcare value chain by a new generation of biomarkers. The presentation will be available online at http://www.kinemed.com/webcast. "Advances in the state-of-the-art in biomarkers, as we move from traditional static measures to dynamic measurements of exquisite precision and unparalleled resolution, herald a revolution in the ability of scientists and clinicians to link biochemical interrogation of living cells with clinical output measures and, in fact, the overall health of the organism. These new measures of the true, underlying state of biological systems open up huge possibilities for commercialization," said Mr. Fineman. "Recent flagship collaborations that we are able to highlight in traditionally intractable areas, such as chronic neurodegeneration, are the tip of an iceberg across the healthcare spectrum. This is truly translational science, where the same biomarker can be used from the lab to the clinic to enhance drug development, provide clinical diagnosis, be paired with drugs to create companion diagnostics and enable monitoring of disease treatment and resolution. The application of these technologies will therefore be critical in aligning the realization of personalized medicine and improved health outcomes with more effective management of our nation`s healthcare costs." Mr. Fineman`s talk will include recent examples of biomarkers identified in blood plasma and cerebrospinal fluid that show accurate correlation with disease metrics across a number of key indications, holding the potential to replace traditional biopsy samples with a "virtual biopsy" in fluid specimens that can be collected with a minimum of cost and complexity. About the 2013 15th Annual BIO CEO & Investor Conference Organized by the Biotechnology Industry Organization, the 15th Annual BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. For more information about the 2013 BIO CEO & Investor Conference, please visit: http://www.bio.org/events/conferences/bio-ceo-investor-conference About KineMed, Inc. KineMed, Inc., is a leading diagnostic biomarker discovery and drug development company focused on causal pathway discovery and the pairing of medicines with diagnostics for integrated disease management. KineMed works with collaborators and clients to develop biomarkers that provide predictive, actionable information to dramatically improve de-risk and accelerate drug discovery, development and disease management decisions. KineMed`s technology reveals dynamic causal processes of disease rather than isolated molecular targets and provides precise measures of therapeutic effectiveness on these processes, offering "yes/no" to key treatment questions: "Is this drug right for the patient?" and "Is the drug working?" KineMed`s biomarkers are fully translational from animal to man, seamlessly harmonizing data across pre-clinical and clinical phases of development, through to the diagnosis and management of diseases including fibrotic, metabolic, cardiovascular disease, and cancer. KineMed`s platform addresses key industry needs: * Illuminating causal mechanisms of disease: Generating pivotal knowledge for developing novel therapeutics that target underlying biochemical causes rather than symptoms * Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context * Reduce late-stage attrition: Early, decision-relevant metrics of drug activity to remove costly failures late in the development cycle and improve the overall ROI of R&D spend * Establish patient pre-selection criteria: Enabling more tightly focused patient selection for clinical trials to target increased response rate in a segmented population * Provide the link to pair medicines with diagnostics: Custom-developed assays create companion diagnostic tests for personalized medicine In addition to partnerships, KineMed also has an active pipeline of therapeutics and diagnostics in development and is seeking further broad collaborations with biotechnology, pharmaceutical, CRO, histopathology, diagnostics and medical instrument partners. For more information about KineMed, please visit: http://www.kinemed.com KineMed, Inc. Ravi Kiron, Ph.D., MBA, Chief Business Officer Tel: 510-655-6525 ext. 105 Cell: 650-224-3836 firstname.lastname@example.org Copyright Business Wire 2013
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters press on |
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Singapore hit by rare outbreak of rioting, 27 arrested |
- Venezuela's Maduro to raise pressure on business after local vote